CytoDyn (CYDY) Return on Capital Employed (2011 - 2026)
CytoDyn's (CYDY) quarterly Return on Capital Employed came in at 103.51% in Q1 2026, up 12054.0% YoY from N/an in Q1 2025, and up 114.27% on a QoQ basis from 48.31% in Q4 2025.
CytoDyn (CYDY) Return on Capital Employed (2011 - 2026) Analysis & Trends
CytoDyn (CYDY) has 16 years of Return on Capital Employed data on file, last reported at 103.51% in Q1 2026.
- Quarterly Return on Capital Employed rose 12054.0% year-over-year to 103.51% in Q1 2026, while the trailing twelve-month figure through Feb 2026 was 103.51% (up 12054.0% YoY) and the FY2025 annual result came in at 17.27%, down 4202.0% from the prior year.
- Return on Capital Employed rose to 103.51% in Q1 2026, from 48.31% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 523.3% in Q1 2022 to a low of 19.65% in Q4 2024.
- A 5-year average of 80.18% and a median of 33.03% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 7050611 bps — and 2026, when it surged 12054 bps.
- Tracing CYDY's Return on Capital Employed over 5 years: stood at 125.12% in 2022, then slumped by 89 bps to 13.95% in 2023, then tumbled by 241 bps to 19.65% in 2024, then jumped by 346 bps to 48.31% in 2025, then jumped by 114 bps to 103.51% in 2026.
- The last three Return on Capital Employed figures came in at 103.51% (Q1 2026), 48.31% (Q4 2025), and 33.03% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | 103.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 103.51% |
| Nov 30, 2025 | 48.31% |
| Aug 31, 2025 | 33.03% |
| May 31, 2025 | -18.98% |
| Feb 28, 2025 | -17.03% |
| Nov 30, 2024 | -19.65% |
| Aug 31, 2024 | -17.99% |
| May 31, 2024 | 24.58% |
| Feb 29, 2024 | 12.70% |
| Nov 30, 2023 | 13.95% |
| Aug 31, 2023 | 30.27% |
| May 31, 2023 | 37.98% |
| Feb 28, 2023 | 104.86% |
| Nov 30, 2022 | 125.12% |
| Aug 31, 2022 | 142.71% |
| May 31, 2022 | 236.32% |
| Feb 28, 2022 | 523.30% |
| Nov 30, 2021 | 875.89% |
| Aug 31, 2021 | 904.41% |
| May 31, 2021 | 352.07% |